Skip to content

A real-world safety study of upadacitinib in Chinese patients with inflammatory bowel disease

A real-world safety study of upadacitinib in Chinese patients with inflammatory bowel disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090481
Enrollment
Unknown
Registered
2024-09-30
Start date
2024-10-04
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

CD patients:No intervention
UC patients:No intervention

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who visited the Department of Gastroenterology of multiple centers such as the Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine (lead unit) and were diagnosed with Crohn's disease or ulcerative colitis between January 2023 and June 2024. 2. Patients aged = 18 years old should take upadacitinib. 3. Patients who are clinically diagnosed by a doctor as needing to use upadacitinib to treat Crohn's disease or ulcerative colitis.

Exclusion criteria

Exclusion criteria: 1. The subject has any active, chronic or recurrent infections that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study, including hepatitis B or hepatitis C virus, recurrent/disseminated herpes zoster or known history of HIV; 2. The subject has active tuberculosis or meets tuberculosis exclusionary parameters; 3. The subject has a history of malignancy other than a successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix; 4. The subject has prior or current gastrointestinal dysplasia, other than completely removed lowgrade dysplastic lesion in any biopsy performed during or before the screening endoscopy; 5. The subject has a history of spontaneous gastrointestinal perforation (other than appendicitis or mechanical injury), diverticulitis or significantly increased risk of GI perforation per investigator's judgment; 6. The subject has a history of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same; 7. Screening laboratory and other analyses show any of the following abnormal results: (1) Serum Aspartate Transaminase (AST) or Alanine Transaminase (ALT) > 2 × upper limit of normal (ULN); (2) Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula 160 mmHg or diastolic blood pressure > 100 mmHg; (3) Prior history of thrombotic events, including deep vein thrombosis and pulmonary embolism; (4) Known inherited conditions that predispose to hypercoagulability; 9. The subject is considered as disadvantaged groups, including subjects who have psychiatric disorders or cognitive impairment, who are critically ill, or who are pregnant or juveniles.

Design outcomes

Primary

MeasureTime frame
Adverse Events;Medication status;Disease characteristics;Infection Screening;

Secondary

MeasureTime frame
Demographic characteristics;

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

caoq@zju.edu.cn+86 135 8870 6896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026